Volunteer in AstraZeneca Covid-19 vaccine trial dies in Brazil

·2 min read

A volunteer in AstraZeneca's Covid-19 vaccine trial has died in Brazil, the country's National Health Surveillance Agency said Wednesday.

The agency, Anvisa, said in a statement that it was formally notified of the death on Monday.

Full coverage of the coronavirus outbreak

The vaccine candidate is being developed with the University of Oxford.

In a statement to NBC News, AstraZeneca said that the trial would continue.

"We cannot comment on individual cases in an ongoing trial of the Oxford vaccine as we adhere strictly to medical confidentiality and clinical trial regulations, but we can confirm that all required review processes have been followed," the statement said. "All significant medical events are carefully assessed by trial investigators, an independent safety monitoring committee and the regulatory authorities. These assessments have not led to any concerns about continuation of the ongoing study."

"All relevant critical events observed among participants in the control group or any group receiving a vaccine against COVID-19 are reviewed by an independent safety committee," the University of Oxford said in a statement. "Careful analysis of this case in Brazil, raised no doubt as to the safety of the ongoing clinical study. A review by the independent committee and Brazilian regulatory agencies recommend that the study should continue.”

Related: Just a handful of volunteers received their first doses of AstraZeneca's Covid-19 vaccine candidate before the trial was put on hold.

Ian Jones, a professor of virology at the University of Reading in the United Kingdom said that it was likely the death was not vaccine-related.

"Without details it’s impossible to know what has happened in this case but as the trial is continuing, I think we can assume the circumstances of the death were such that it was clearly not vaccine related," Jones said in a statement.

AstraZeneca's phase 3 clinical trial was put on hold in early September after a study participant in the U.K. developed a spinal cord injury. The trials have since resumed in the U.K. as well as in Brazil, though they remain on hold in the U.S.

Follow NBC HEALTH on Twitter & Facebook.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting